The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers

Weinberger, Myron H.

doi:10.1016/0002-9343(91)90480-l

Cited by 9 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested that thiazide‐type diuretic therapy has an additive effect on BP reduction with all drug classes other than calcium channel blockers (CCBs) 22–23 . It was believed that the natriuretic effect of CCB therapy effectively replaced that of a thiazide‐type diuretic; thus, if both drug classes were to be given together, the volume/vasodilator axis would be redundantly interrupted 24 .…”

Section: Additivity With Nondiabetic Antihypertensive Drug Classesmentioning

confidence: 99%

Thiazide‐Type Diuretics: Ongoing Considerations on Mechanism of Action

Sica

2004

J of Clinical Hypertension

View full text Add to dashboard Cite

Thiazide-type diuretics have enjoyed a considerable success in the management of hypertension. These drugs have assumed a standard-of-care position in the minds of many health care providers; however, a number of questions remain unresolved in relation to their use. Such questions include issues of mechanism of action, comparability to loop-diuretics in their actions, class-effect, and the basis for their additivity with non-diuretic antihypertensive medication classes. Understanding these issues is important to the effective use of these compounds.

show abstract

Section: Additivity With Nondiabetic Antihypertensive Drug Classesmentioning

confidence: 99%

Thiazide‐Type Diuretics: Ongoing Considerations on Mechanism of Action

Sica

2004

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…The natriuretic action of CCB and the clinical relevance of this effect have been the topic of several recent investigations (12). Phenylalkylamines, benzothiazepines, and dihydropyridines are similar in this regard.…”

Section: Organ and Site-specific Issues The Kidneymentioning

confidence: 99%

Calcium Channel Blockers in Current Medical Practice: An Update for 1993

Luft

Haller²

1993

Clinical and Experimental Hypertension

View full text Add to dashboard Cite

Calcium channel blocking drugs (CCB) have been used to lower blood pressure since 1970. Three classes are currently available, the phenylalkylamines, the benzothiazepines, and the dihydropyridines. The structure of the L-type, voltage dependent calcium channel has been elucidated with molecular techniques and the different binding sites of the various CCB described. CCB have specific effects at the site of target organs. In the kidney, all classes produce natriuresis. Their action appears independent of the level of salt intake. CCB may favorably influence the course of chronic renal disease; the results of a trial comparing nifedipine to the converting enzyme inhibitor captopril showed no difference between the two drugs. CCB may impede the progression of atherosclerosis in the coronary arteries; a prospective study of nifedipine on coronary artery morphology supports this view. In the brain, nimodipine improves the outcome of patients with stroke from subarachnoid hemorrhage. Positive effects on patients with ischemic stroke have not been corroborated. CCB are approved primary treatment for patients with hypertension and are readily combined with other antihypertensive agents. They are well tolerated and have no adverse metabolic side effects. The advent of molecular pharmacology will advance current efforts to develop new CCB, which are highly selective in their site and mode of action.

show abstract